TargetMol

(E/Z)-ZINC09659342

Product Code:
 
TAR-T9986
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T9986-1mg1mg£171.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9986-5mg5mg£322.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9986-1mL1 mL * 10 mM (in DMSO)£348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9986-10mg10mg£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9986-25mg25mg£707.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9986-50mg50mg£978.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9986-100mg100mg£1,291.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9986-500mg500mg£2,456.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
(E/Z)-ZINC09659342 is an inhibitor of Lbc-Rho A interaction.
CAS:
591726-26-0
Formula:
C23H15F3N2O4
Molecular Weight:
440.37
Pathway:
Cell Cycle/Checkpoint
Purity:
0.98
SMILES:
O=C(C1=CC=C(C=C1)N2N=C(C(C2=O)=CC3=CC=C(O3)C4=CC=CC(C(F)(F)F)=C4)C)O
Target:
Rho

References

Francesca FANELLI, et al. Compounds and composition for use in the inhibition of the lbc-rhoa interaction, in particular for the treatment of cancer. WO2015028929A1.